Hetty E Carraway
Hetty E Carraway
Low- and intermediate-risk myelodysplastic syndromes (LR-MDS and Int-MDS, respectively) are characterized by ineffective hematopoiesis, along with the presence of at least 10% dysplasia in one cell line, accompanied by a low number and dept...
Hemophagocytic lymphohistiocytosis: do we have a solution for TMI (too much inflammation)? [0.03%]
噬血细胞综合征：如何解决“过多炎症”问题？
Paul La Rosée,Rafal Machowicz
Paul La Rosée
Hemophagocytic lymphohistiocytosis (HLH) and the related HLH-spectrum disorders macrophage activation syndrome, macrophage activation-like syndrome, and treatment-associated immune-effector-cell-associated HLH-like syndrome are extreme form...
Managing patients with a history of arterial disease and new venous thromboembolism [0.03%]
动脉疾病史患者发生新型静脉血栓栓塞的诊疗注意事项
Echo Deng,Freda H Passam
Echo Deng
Arterial and venous thromboses differ in pathophysiology but share overlapping risk factors such as obesity, metabolic syndrome, and aging. Patients with established arterial disease, such as coronary artery disease, stroke, and peripheral ...
Maria Domenica Cappellini,Ali T Taher,Irene Motta
Maria Domenica Cappellini
Although the management of β-thalassemia has improved significantly, patients still suffer from many complications, including thrombotic events. A hypercoagulable state has been demonstrated in these conditions, particularly in non-transfu...
Where do immunotherapies stand in management of acute leukemia in adults? [0.03%]
成人急性白血病免疫疗法的治疗地位如何？
Nicolas Boissel
Nicolas Boissel
Immunotherapies have significantly transformed the treatment landscape of acute leukemia in adults, most notably in B-cell acute lymphoblastic leukemia (B-ALL). Blinatumomab and inotuzumab ozogamicin have become established treatments, enha...
Updates in antithrombotic therapy in coronary and peripheral artery disease [0.03%]
冠心病和外周动脉疾病抗栓治疗的最新进展
Amy West Pollak
Amy West Pollak
Atherosclerotic cardiovascular disease (ASCVD) encompasses a spectrum of vascular conditions, including coronary artery disease (CAD) and lower extremity peripheral artery disease (PAD), which frequently coexist. In the setting of ASCVD, th...
Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T-cell persistence in ALL [0.03%]
CAR-T治疗后的维持治疗？我们做到了吗？降低ALL患者抗CD19 CAR-T细胞丢失后复发风险的方法
Maria Gabelli,Sara Ghorashian
Maria Gabelli
Anti-CD19 chimeric antigen receptor (CAR) T cells can induce complete remission in the majority of children and young adults affected by multiple relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) and provide potential ...
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL? [0.03%]
在儿童B系急淋治疗中，BiTE处于主导地位，CAR-T如何分一杯羹？
Amanda M Li,Shannon L Maude
Amanda M Li
T-cell engaging immunotherapies have transformed the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL). First revolutionizing outcomes for relapsed and refractory disease, these therapies are now being incorporated and stud...
Post-HCT maintenance therapy for AML: who, when, why, how long? [0.03%]
allo-HSCT后AML的维持治疗：谁、何时、为何、多久？
Mark Levis
Mark Levis
Patients with acute myeloid leukemia (AML) often undergo allogeneic hematopoietic cell transplantation (HCT) as it represents a highly effective treatment to prevent relapse of their disease. While HCT is an important part of curative thera...
Andrew J Davies
Andrew J Davies
The high-grade B-cell lymphomas represent a pathologically and clinically heterogeneous group of mature B-cell malignancies. With modern molecular diagnostics and genomic studies, they are becoming increasingly resolved as we understand mor...